Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7376-7386

  Putluri, Nagireddy ^a   Shojaie, Ali ^e,k   Vasu, Vihas T ^c,l   Vareed, Shaiju K ^a   Nalluri, Srilatha ^c   Putluri, Vasanta ^a   Thangjam, Gagan Singh ^c   Panzitt, Katrin ^a   Tallman, Christopher T ^f   Butler, Charles ^g   Sana, Theodore R ^h   Fischer, Steven M ^h   Sica, Gabriel ^g   Brat, Daniel J ^g   Shi, Huidong ^b,c   Palapattu, Ganesh S ^b   Lotan, Yair ⁱ   Weizer, Alon Z ^f   Terris, Martha K ^c,d   Shariat, Shahrokh F ^j   Michailidis, George ^e   Sreekumar, Arun ^a,c   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h AGILENT TECHNOLOGIES   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2E1; DNA; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE T1; XENOBIOTIC AGENT;

ARTICLE; BIOPROCESS; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; EARLY DIAGNOSIS; EXPLORATORY RESEARCH; GENE MAPPING; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR GROWTH; URINALYSIS; XENOBIOTIC METABOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84255199617     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1154     Document Type: Article

References (31)

1. ACS. Cancer facts and figures 2010. American Cancer Society, Atlanta, GA; 2010.
2. van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, van der Kwast TH, et al. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int 2008;101:1106-10. (Pubitemid 351502647)
3. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18; discussion 18.
4. Pasikanti KK, Esuvanranathan K, Ho PC, Mahendran R, Kamaraj R,Wu Q, et al. Noninvasive Urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 2010;9:2988-95.
5. Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 2008;179:2422-6.
6. Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ, Goebell PJ, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010;28;389-400.
7. Putluri N, Shojaie A, Vasu VT, Nalluri S, Vareed SK, Putluri V, et al. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One 2011;6:e21417.
8. Smyth GK. Limma: linear models for microarray data'bioinformatics and computational biology solutions using R and bioconductor. In: Gentleman VC R, Dudoit S, Irizarry R, Huber W, editor. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
9. Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, Lumley T, et al. gplots: Various R programming tools for plotting data. In: Warnes GR, editor. R package version 2.8.0. ed; 2010.
10. Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 2008;24:1461-2. (Pubitemid 351851002)
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach in multiple testing. J Roy Statist Soc 1995;Series B 57.
12. Wehrens RM, B.H. pls: Partial least squares regression (PLSR) and principal component regression (PCR). R package version 21-0 2007 [cited]. Available from: http://mevik.net/work/software/pls.html.
13. Wing J, Weston S, Wlliams A, Keefer C, Engelhardt A. caret: Classification and regression training. R package In: Kuhn M, editor. version 4.67. ed; 2010.
14. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
16. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005;21:4067-8. (Pubitemid 41631851)
17. Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R, Kalyana-Sundaram S, et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 2010;9:298-312.
18. Sepai O, Sabbioni G. Biomonitoring workers exposed to arylamines: application to hazard assessment. Adv Exp Med Biol 1996;387:451-5. (Pubitemid 26259860)
19. Carreon T, Hein MJ, Viet SM, Hanley KW, Ruder AM, Ward EM. Increased bladder cancer risk among workers exposed to o-toluidine and aniline: a reanalysis. Occup Environ Med 2010;67:348-50.
20. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-9. (Pubitemid 41338989)
21. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007;9:443-54. (Pubitemid 46799988)
22. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008;98:466-73. (Pubitemid 351161244)
23. Vallot C, Stransky N, Bernard-Pierrot I, Herault A, Zucman-Rossi J, Chapeaublanc E, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011;103;47-60.
24. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, et al. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst 2009;101:1553-61.
25. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009;41:259-66.
26. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environmental Health Perspectives; 1979:71-79. (Pubitemid 9190956)
27. Int J Epidemiol 2007;36:11-8.
28. Fanlo A, Sinues B, Mayayo E, Bernal L, Soriano A, Martinez-Jarreta B, et al. Urinary mutagenicity, CYP1A2 and NAT2 activity in textile industry workers. J Occup Health 2004;46:440-7. (Pubitemid 40011862)
29. Grando JP, Kuasne H, Losi-Guembarovski R, Sant'ana Rodrigues I, Matsuda HM, Fuganti PE, et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med 2009;9:21-8.
30. Roos PH, Bolt HM. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert opinion on drug metabolism & toxicology 2005;1:187-202.
31. Thier R, Bruning T, Roos PH, Bolt HM. Cytochrome P450 1B1, a new keystone in gene-environment interactions related to human head and neck cancer? Arch Toxicol 2002;76:249-56. (Pubitemid 34639519)